TNFSF10 and mature T-cell and NK-cell non-Hodgkin lymphoma: Our research suggests that targeting the extrinsic pathway may offer a mechanistic advantage and implicates a role for combination of STAT5 inhibition with death receptor signaling agonists as a future therapeutic approach in PTCL, although effective TRAIL agonists are still in development [58].